More than the sum of its parts

 The University of Prince Edward Island today licensed a promising piece of medical technology to Carmel Biosciences, a biomedical company based in Tucker, Georgia. The technology is a “co-drug” with powerful anti-inflammatory activity. 

“This novel compound is derived from naturally occurring products with proven safety and efficacy in humans,” said Dr. Tarek Saleh, chair of Biomedical Sciences at UPEI’s Atlantic Veterinary College. “We’ve bonded them chemically and created a unique compound. This new compound shows great potential as an anti-inflammatory for use in neurological disorders such as multiple sclerosis, Parkinson’s disease and stroke.”

Dr. Saleh developed the new compound, patent-pending under the name UPEI-100, with Dr. Bobby Khan, a physician and investigator at the Atlanta Vascular Research Foundation and a past visiting Fulbright Scholar to UPEI. 

“The Fulbright Scholarship allowed me to meet and build this collaboration with Dr. Saleh,” said Dr. Khan. “This new technology is one of several exciting yields from this successful collaboration. I’m thankful to John and Judy Bragg, the Fulbright Commission, and Dr. Katherine Schultz for making it possible.” 

UPEI-100 is fully owned by the university. Today’s agreement licenses the technology to Carmel Biosciences, which will guide it through pre-clinical drug testing. 

“We think this compound has an exciting future as a drug for people with neurological disorders,” said Dr. Khan. “But there are numerous regulatory hoops to jump through before then. I think this partnership is a great step.” 

Frank Kelly, a director of Carmel Biosciences and past vice-president of the Coca-Cola Company, said he’s impressed by how collaborations around UPEI-100 are helping to streamline pre-clinical research. 

“It often takes two years, and more than four-million dollars, to take a drug just through the pre-clinical phases of regulatory approval,” said Kelly. “Carmel Biosciences has partnered with a well-established contract research organization in India who will be able to do it in half the time, and at a fraction of the cost.” 

The licensing deal between UPEI and Carmel Biosciences was negotiated and executed by Three Oaks Innovations Inc., an independent company, and the bridge between UPEI and industry. 

“This is another exciting piece of UPEI technology with the potential to make a real difference in people’s lives,” said Sophie Theriault, director of Three Oaks Innovations Inc. “UPEI, through commercialization partnerships such as this one, is a key player in the province's economic development and sustainability. The potential of this agreement is really limitless.” 

 “Research at UPEI is a driving force behind innovation on Prince Edward Island. This is where creativity and knowledge come together to create exciting new opportunities such as UPEI-100,” said Dr. Alaa Abd-El-Aziz, president of UPEI. “I want to congratulate Dr. Saleh and Dr. Khan on this exciting day, and I want to thank Sophie and her team at Three Oaks Innovations Inc. for helping to make it happen.” 

UPEI-100 is the first of what is expected to be several new compounds from the collaboration between Dr. Saleh and Dr. Khan, and begins a presence on Prince Edward Island for Carmel Bioscience.

Contact: Dave Atkinson
Research Communications
datkinson@upei.ca, (902)620-5117

Johne's happens

Originally posted at innovationcanada.ca, which showcases research excellence in Canada.
 

Trudging through a dairy farm to collect manure samples isn’t exactly glamorous work, but the odorous task is starting to have a big impact on the health of dairy cattle in Atlantic Canada — and it will save the dairy industry millions of dollars each year.

Technicians at the University of Prince Edward Island’s (UPEI) Atlantic Veterinary College began collecting these samples this past spring as part of a new study designed to understand and eliminate an insidious disease that affects cattle throughout North America — Johne’s (pronounced YO-neez) disease. Cows suffering from Johne’s do not display many symptoms, so it is hard to detect and diagnose. While generally not fatal, the disease affects the amount of milk cows produce and, as a result, the bottom line of farming operations.

Greg Keefe, professor of dairy health management at UPEI, is spearheading the Atlantic Johne’s Disease Initiative (AJDI), which employs a battery of state-of-the-art tests to detect the presence of the disease on dairy farms throughout the region. The project is funded by the four dairy farmer boards in Atlantic Canada in partnership with the four provincial Agricultural Adaptation Councils and Innovation PEI. The work is supported by Canada Foundation for Innovation (CFI) investments.

The CFI funded several pieces of testing equipment in the AJDI lab. A broth-culture system that Keefe refers to as the “gold standard test” grows bacteria from cow feces to see whether there are traces of the organism that causes Johne’s — a test that takes seven to eight weeks to complete. This technology replaces a less sensitive PCR (polymerase chain-reaction) test that takes about twice as long. PCR is now used primarily as a confirmatory test on broth isolates. Two other testing systems that look for antibodies in blood or milk aren’t as accurate but generate results in 48 hours. Being able to access a variety of results from the four testing systems at different stages is crucial for the AJDI program, says Keefe. “I believe we are the only lab in Canada that is USDA proficiency-tested for all four methods.”

Johne’s disease is contracted by calves soon after birth, but the main symptom — a thickening of the cow’s digestive tract that limits its ability to absorb nutrients — doesn’t begin to appear for three to five years. Cattle that contract Johne’s lose weight and produce less milk, which leads to a loss of revenue — about $2,500 per 50-cow herd per year, according to a 2002 Canadian study. In Canada, with just under a million dairy cows, the total loss is potentially significant. Keefe estimates that anywhere from 25 to 40 percent of dairy herds in Canada are currently infected.

The dairy industry is also concerned about the possibility of disease-based restrictions on cattle movement, as we have seen with other animal health issues in the past decade. “If we don’t take steps now to limit Johne’s,” says Keefe, “other countries may look at placing non-tariff trade barriers on our dairy industry.”

Once evidence of Johne’s disease has been detected in a herd through the initial environmental culture, the AJDI team works with the farmer to develop a control plan that uses risk-management techniques to limit the spread of the disease. Those veterinary visits, says Keefe, are the business end of the program: “That’s where we will see our improvements in herd health, through that one-on-one communication with farmers.”

After an initial control strategy has been successfully implemented, a herd becomes eligible for funding for testing individual cows to refine the plan. So far, about 10 percent of Atlantic Canada’s 700 dairy farms have signed on to the AJDI. Keefe hopes to enroll at least 60 percent over the next couple of years. “This program is already being looked at as a model for managing Johne’s disease in other regions,” he says. “We’ve been getting calls from dairy industry personnel all over North America asking for information about our work.”